Thermo Fisher Scientific Inc. $TMO Stake Cut by Pathway Financial Advisers LLC

Pathway Financial Advisers LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 74.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 400 shares of the medical research company’s stock after selling 1,187 shares during the period. Pathway Financial Advisers LLC’s holdings in Thermo Fisher Scientific were worth $270,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Keeler Thomas Management LLC raised its stake in Thermo Fisher Scientific by 0.9% in the third quarter. Keeler Thomas Management LLC now owns 1,928 shares of the medical research company’s stock worth $1,301,000 after buying an additional 17 shares in the last quarter. Tsfg LLC boosted its position in Thermo Fisher Scientific by 20.4% during the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 19 shares in the last quarter. Welch Group LLC raised its position in shares of Thermo Fisher Scientific by 1.8% in the 3rd quarter. Welch Group LLC now owns 1,089 shares of the medical research company’s stock worth $735,000 after acquiring an additional 19 shares in the last quarter. Renasant Bank lifted its stake in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after purchasing an additional 20 shares during the last quarter. Finally, Strengthening Families & Communities LLC boosted its position in Thermo Fisher Scientific by 0.4% during the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock valued at $3,187,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: The board authorized up to $5 billion in share repurchases, replacing an authorization with $1 billion remaining. The new program has no expiration date and could support shareholder returns and demand for the stock. Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
• Positive Sentiment: Thermo Fisher introduced lower-priced qPCR master mixes, positioning its products for labs seeking reliable testing tools while managing budgets. The launch may broaden product appeal, though its near-term financial impact is not specified. Thermo Fisher Scientific Introduces Value-Priced AmpSure Universal qPCR Master Mixes
• Positive Sentiment: An investor-letter report cited improving biopharma spending and said TMO was a strong contributor after a 27% quarterly gain. That supports the demand outlook, but also highlights the stock’s recent run-up. Improving Biopharma Spending Lifts Thermo Fisher
• Neutral Sentiment: Industry reports forecast growth in mRNA manufacturing, protein labeling and Q-TOF mass spectrometry markets, areas relevant to Thermo Fisher. These are broad market projections, not company-specific sales or earnings updates. mRNA Manufacturing Service Market Report 2026
• Negative Sentiment: After substantial recent gains, investors may be taking profits; TMO’s elevated valuation could also make shares sensitive to market expectations. The articles provide no specific deterioration in the company’s outlook to explain the weakness.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa Britt sold 2,831 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total transaction of $1,999,959.95. Following the transaction, the vice president owned 11,560 shares in the company, valued at approximately $8,166,562. This represents a 19.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc Casper sold 275 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 50,046 shares of company stock valued at $30,779,192. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 4.1%

Thermo Fisher Scientific stock opened at $677.28 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market cap of $250.95 billion, a PE ratio of 35.72, a price-to-earnings-growth ratio of 2.88 and a beta of 0.84. The stock has a 50-day moving average of $659.74 and a two-hundred day moving average of $554.40. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $712.17.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the firm earned $5.79 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on TMO. Sanford C. Bernstein increased their price target on shares of Thermo Fisher Scientific from $520.00 to $575.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Stifel Nicolaus lifted their price objective on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Scotiabank started coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “outperform” rating for the company. Barclays increased their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $683.64.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.